CZ298812B6
(cs)
|
1996-07-01 |
2008-02-13 |
Dr. Reddy's Laboratories Limited |
Azolidindionové deriváty, způsob jejich přípravy, farmaceutické kompozice s jejich obsahem a jejich použití v léčbě diabetu a příbuzných nemocí
|
USRE39266E1
(en)
*
|
1996-07-01 |
2006-09-05 |
Dr. Reddy's Laboratories, Limited |
Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
|
US6313113B1
(en)
|
1997-04-15 |
2001-11-06 |
Reddy-Cheminor, Inc. |
Heterocyclic compounds having antidiabetic, hypolipidemic and antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
|
US6369067B1
(en)
|
1997-10-27 |
2002-04-09 |
Dr. Reddy's Research Foundation |
Monocyclic compounds and their use in medicine: process for their preparation and pharmaceutical compositions containing them
|
US6265401B1
(en)
|
1997-10-27 |
2001-07-24 |
Reddy-Cheminor, Inc. |
Bicyclic compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them
|
US6444816B1
(en)
|
1997-10-27 |
2002-09-03 |
Dr. Reddy's Research Foundation |
Fused 7-oxo-pyrimidinyl compounds, preparation, composition and use thereof
|
AU1198699A
(en)
|
1997-10-27 |
1999-04-23 |
Dr. Reddy's Research Foundation |
Novel heterocyclic compounds and their use in medicine, process for their reparation and pharmaceutical compositions containing them
|
AU752059B2
(en)
|
1997-10-27 |
2002-09-05 |
Dr. Reddy's Laboratories Limited |
Bicyclic compounds, process for their preparation and pharmaceutical compositions containing them
|
CN100376560C
(zh)
*
|
1997-10-27 |
2008-03-26 |
雷迪实验室有限公司 |
新型三环化合物和其作为药物的用途;其制备方法和包含该化合物的药物组合物
|
US6440961B1
(en)
|
1997-10-27 |
2002-08-27 |
Dr. Reddy's Research Foundation |
Tricyclic compounds and their use in medicine: process for their preparation and pharmaceutical compositions containing them
|
WO1998045291A1
(en)
*
|
1997-12-02 |
1998-10-15 |
Dr. Reddy's Research Foundation |
Substituted thiazolidinedione and oxazolidinedione having antidiabetic, hypolipidemia and antihypertensive properties
|
WO1999008501A2
(en)
*
|
1998-04-23 |
1999-02-25 |
Dr. Reddy's Research Foundation |
New heterocyclic compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them
|
IN187716B
(de)
*
|
1998-09-14 |
2002-06-15 |
Reddy Research Foundation |
|
US6531596B1
(en)
|
1998-10-29 |
2003-03-11 |
Dr. Reddy's Laboratories Ltd. |
Process for the preparation of new antidiabetic agents
|
CN1323300A
(zh)
*
|
1998-10-29 |
2001-11-21 |
雷迪研究基金会 |
制备新的抗糖尿病剂的改进方法
|
AU776299B2
(en)
*
|
1998-12-01 |
2004-09-02 |
Dr Reddy's Laboratories, Inc. |
New pharmaceutical composition and the process for its preparation
|
AU773505B2
(en)
*
|
1999-06-18 |
2004-05-27 |
Merck & Co., Inc. |
Arylthiazolidinedione and aryloxazolidinedione derivatives
|
EP1634605A3
(de)
|
2000-03-08 |
2006-10-11 |
Novo Nordisk A/S |
Behandlung von Dyslipämie bei einem Patienten mit Typ 2 Diabetes
|
US6667300B2
(en)
|
2000-04-25 |
2003-12-23 |
Icos Corporation |
Inhibitors of human phosphatidylinositol 3-kinase delta
|
EP1939203B1
(de)
*
|
2000-04-25 |
2014-11-19 |
ICOS Corporation |
Hemmer der delta-Isoform der menschlichen Phosphatidyl-Inositol-3-Kinase
|
SI2223922T1
(sl)
|
2000-04-25 |
2016-04-29 |
Icos Corporation |
Inhibitorji humane fosfatidil-inositol 3-kinazne delta izoforme
|
AU2001260083A1
(en)
|
2000-05-26 |
2001-12-03 |
Dr. Reddy's Research Foundation |
New pharmaceutical composition and the process for its preparation
|
WO2001091751A1
(en)
*
|
2000-05-30 |
2001-12-06 |
Novo Nordisk A/S |
New pharmaceutical composition and the process for its preparation
|
US6559335B2
(en)
|
2000-09-22 |
2003-05-06 |
Dr. Reddy's Laboratories Limited |
Process for the preparation of 3-aryl-2-hydroxy propanoic acid
|
WO2002060443A1
(en)
*
|
2000-12-18 |
2002-08-08 |
Smithkline Beecham Corporation |
Thiazolidinediones
|
SK7822003A3
(en)
|
2000-12-21 |
2003-12-02 |
Aventis Pharma Gmbh |
Novel 1,2-diphenzylazetidinones, method for producing the same, medicaments containing said compounds, and the use thereof for treating disorders of the lipid metabolism
|
WO2002062798A2
(en)
*
|
2001-02-05 |
2002-08-15 |
Dr. Reddy's Laboratories Ltd. |
Salts of pyrimidine derivatives for use against coronary heart disease and atherosclerose
|
WO2002069994A2
(en)
|
2001-03-07 |
2002-09-12 |
Novo Nordisk A/S |
Combined use of derivatives of glp-1 analogs and ppar ligands
|
DE10142660A1
(de)
|
2001-08-31 |
2003-03-20 |
Aventis Pharma Gmbh |
Verwendung von Derivaten von C2-substituierten Indan-1-ol-Systemen zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Obesitas
|
PE20021091A1
(es)
|
2001-05-25 |
2003-02-04 |
Aventis Pharma Gmbh |
Derivados de fenilurea sustituidos con carbonamida y procedimiento para su preparacion
|
HUP0401318A3
(en)
|
2001-08-22 |
2008-03-28 |
Sanofi Aventis Deutschland |
Combined preparations containing 2,3,4,5-tetrahydro-benzo[b]thiepine-1,1-dioxide derivatives and other active substances, and the use thereof
|
DE10142666A1
(de)
|
2001-08-31 |
2003-03-20 |
Aventis Pharma Gmbh |
Verwendung von C2-substituierten Indan-1-ol-Systemen zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Obesitas
|
DE10142665B4
(de)
|
2001-08-31 |
2004-05-06 |
Aventis Pharma Deutschland Gmbh |
C2-Disubstituierte Indan-1-one und ihre Derivate
|
RS50889B
(sr)
|
2001-08-31 |
2010-08-31 |
Sanofi-Aventis Deutschland Gmbh. |
Derivati diaril-cikloalkila, postupak za njihovu proizvodnju i njihova primena u svojstvu ppar aktivatora
|
DE10142662B4
(de)
|
2001-08-31 |
2004-07-08 |
Aventis Pharma Deutschland Gmbh |
Derivate von C2-substituierten Indan-1-ol-Systemen und ihre Verwendung als Arzneimittel
|
DE10142659A1
(de)
|
2001-08-31 |
2003-03-20 |
Aventis Pharma Gmbh |
Verwendung von mehrfach substituierten Indan-1-ol. Systemen zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Obesitas
|
US6884812B2
(en)
|
2001-08-31 |
2005-04-26 |
Aventis Pharma Deutschland Gmbh |
Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmaceuticals
|
DE10142661B4
(de)
|
2001-08-31 |
2004-06-09 |
Aventis Pharma Deutschland Gmbh |
Mehrfach substituierte Indan-1-ol-Systeme und ihre Verwendung als Arzneimittel
|
DE10142667B4
(de)
|
2001-08-31 |
2004-06-09 |
Aventis Pharma Deutschland Gmbh |
C2-substituierte Indan-1-ole und ihre Derivate und ihre Verwendung als Arzneimittel
|
US7399777B2
(en)
|
2001-08-31 |
2008-07-15 |
Sanofi-Aventis Deutschland Gmbh |
Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmceuticals
|
DE10142663B4
(de)
|
2001-08-31 |
2004-08-19 |
Aventis Pharma Deutschland Gmbh |
C2-Disubstituierte Indan-1-ol-Systeme
|
DE10142668A1
(de)
|
2001-08-31 |
2003-03-20 |
Aventis Pharma Gmbh |
Verwendung von C2-substituierten Indan-1-on-Systemen zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Obesitas
|
DE10142722A1
(de)
|
2001-08-31 |
2003-03-27 |
Aventis Pharma Gmbh |
C2-substituierte Indan-1-one und ihre Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
|
EP2243776A1
(de)
|
2001-10-12 |
2010-10-27 |
High Point Pharmaceuticals, LLC |
Substituierte Piperidine und ihre Verwendung zur Behandlung von Histamine H3 Rezeptor bedingten Erkrankungen
|
US7285557B2
(en)
|
2001-10-15 |
2007-10-23 |
Smithkline Beecham P.L.C. |
Pyrimidinones as melanin concentrating hormone receptor 1
|
GB0124627D0
(en)
*
|
2001-10-15 |
2001-12-05 |
Smithkline Beecham Plc |
Novel compounds
|
US7220777B2
(en)
|
2001-10-15 |
2007-05-22 |
Smithkline Beecham P.L.C. |
Lactam derivatives as antagonists for human 11cby receptors
|
CZ2004747A3
(cs)
|
2001-12-21 |
2004-11-10 |
Novo Nordisk A/S |
Deriváty amidů jako GK aktivátory
|
EP1623984B1
(de)
|
2002-03-15 |
2011-11-02 |
Dr. Reddy's Laboratories Limited |
Polymorphin von 5-[4-[[3-Methyl-4-Oxo-3,4-Dihydrochinazolin-2-YL]Methoxy]Benzyl] Thiazolidin-2,4-Dion Kalium Salz
|
US7078404B2
(en)
|
2002-04-11 |
2006-07-18 |
Sanofi-Aventis Deutschland Gmbh |
Acyl-3-carboxyphenylurea derivatives, processes for preparing them and their use
|
US7223796B2
(en)
|
2002-04-11 |
2007-05-29 |
Sanofi-Aventis Deutschland Gmbh |
Acyl-4-carboxyphenylurea derivatives, processes for preparing them and their use
|
US7049341B2
(en)
|
2002-06-07 |
2006-05-23 |
Aventis Pharma Deutschland Gmbh |
N-benzoylureidocinnamic acid derivatives, processes for preparing them and their use
|
US7176193B2
(en)
|
2002-06-19 |
2007-02-13 |
Sanofi-Aventis Deutschland Gmbh |
Acid-group-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
|
US7671047B2
(en)
|
2002-06-19 |
2010-03-02 |
Sanofi-Aventis Deutschland Gmbh |
Cationically substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
|
US7176194B2
(en)
|
2002-06-19 |
2007-02-13 |
Sanofi-Aventis Deutschland Gmbh |
Ring-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
|
JP4881559B2
(ja)
|
2002-06-27 |
2012-02-22 |
ノボ・ノルデイスク・エー/エス |
治療薬としてのアリールカルボニル誘導体
|
DE10231370B4
(de)
|
2002-07-11 |
2006-04-06 |
Sanofi-Aventis Deutschland Gmbh |
Thiophenglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
|
US7262220B2
(en)
|
2002-07-11 |
2007-08-28 |
Sanofi-Aventis Deutschland Gmbh |
Urea- and urethane-substituted acylureas, process for their preparation and their use
|
JP2006502247A
(ja)
|
2002-07-12 |
2006-01-19 |
サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング |
複素環で置換されたベンゾイル尿素、その製造方法および医薬としてのその使用
|
US7141561B2
(en)
|
2002-07-25 |
2006-11-28 |
Sanofi-Aventis Deutschland Gmbh |
Substituted diaryl heterocycles, process for their preparation and their use as medicaments
|
US20040157922A1
(en)
|
2002-10-04 |
2004-08-12 |
Aventis Pharma Deutschland Gmbh |
Carboxyalkoxy-substituted acyl-carboxyphenylurea derivatives and their use as medicaments
|
US7208504B2
(en)
|
2002-10-12 |
2007-04-24 |
Sanofi-Aventis Deutschland Gmbh |
Bicyclic inhibitors of hormone sensitive lipase
|
DE10258007B4
(de)
|
2002-12-12 |
2006-02-09 |
Sanofi-Aventis Deutschland Gmbh |
Aromatische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
|
US20040242583A1
(en)
|
2003-01-20 |
2004-12-02 |
Aventis Pharma Deutschland Gmbh |
Pyrimido[5,4-e][1,2,4]triazine-5,7-diones, processes for preparing them and their use
|
US7179941B2
(en)
|
2003-01-23 |
2007-02-20 |
Sanofi-Aventis Deutschland Gmbh |
Carbonylamino-substituted acyl phenyl urea derivatives, process for their preparation and their use
|
US7390814B2
(en)
|
2003-02-13 |
2008-06-24 |
Sanofi-Aventis Deutschland Gmbh |
Substituted hexahydropyrazino [1,2-a] pyrimidine-4,7-dione derivatives, process for their preparation and their use as medicaments
|
US7652007B2
(en)
|
2003-02-13 |
2010-01-26 |
Sanofi-Aventis Deutschland Gmbh |
Nitrogen-substituted hexahydropyrazino[1,2-A]pyrimidine-4,7-dione derivatives, processes for their preparation and their use as medicaments
|
DE10306250A1
(de)
|
2003-02-14 |
2004-09-09 |
Aventis Pharma Deutschland Gmbh |
Substituierte N-Arylheterozyklen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
|
DE10308353A1
(de)
|
2003-02-27 |
2004-12-02 |
Aventis Pharma Deutschland Gmbh |
Diarylcycloalkylderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
|
US7148246B2
(en)
|
2003-02-27 |
2006-12-12 |
Sanofi-Aventis Deutschland Gmbh |
Cycloalkyl derivatives having bioisosteric carboxylic acid groups, processes for their preparation and their use as pharmaceuticals
|
DE10308352A1
(de)
|
2003-02-27 |
2004-09-09 |
Aventis Pharma Deutschland Gmbh |
Arylcycloalkylderivate mit verzweigten Seitenketten, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
|
DE10308351A1
(de)
|
2003-02-27 |
2004-11-25 |
Aventis Pharma Deutschland Gmbh |
1,3-substituierte Cycloalkylderivate mit sauren, meist heterocyclischen Gruppen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
|
DE10308355A1
(de)
|
2003-02-27 |
2004-12-23 |
Aventis Pharma Deutschland Gmbh |
Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
|
US7501440B2
(en)
|
2003-03-07 |
2009-03-10 |
Sanofi-Aventis Deutschland Gmbh |
Substituted benzoylureidopyridylpiperidine-and-pyrrolidinecarboxylic acid derivatives, processes for preparing them and their use
|
EP1615698B1
(de)
|
2003-04-11 |
2010-09-29 |
High Point Pharmaceuticals, LLC |
Neue amide derivate und deren pharmazeutische verwendungen
|
RU2005140949A
(ru)
*
|
2003-06-27 |
2007-08-10 |
Д-р Редди`с Ресерч Фаундэйшн (IN) |
Композиции, включающие балаглитазон и дополнительные противодиабетические соединения
|
US7008957B2
(en)
|
2003-07-25 |
2006-03-07 |
Sanofi-Aventis Deutschland Gmbh |
Bicyclic cyanoheterocycles, process for their preparation and their use as medicaments
|
US7094800B2
(en)
|
2003-07-25 |
2006-08-22 |
Sanofi-Aventis Deutschland Gmbh |
Cyanopyrrolidides, process for their preparation and their use as medicaments
|
US7094794B2
(en)
|
2003-07-28 |
2006-08-22 |
Sanofi-Aventis Deutschland Gmbh |
Substituted thiazole-benzoisothiazole dioxide derivatives, process for their preparation and their use
|
DE10335092B3
(de)
|
2003-08-01 |
2005-02-03 |
Aventis Pharma Deutschland Gmbh |
Substituierte Benzoylureido-o-benzoylamide, Verfahren zu deren Herstellung und deren Verwendung
|
CA2539596A1
(en)
|
2003-09-30 |
2005-04-07 |
Kilian Waldemar Conde-Frieboes |
Melanocortin receptor agonists
|
EP1679074B1
(de)
|
2003-10-24 |
2010-12-08 |
Santen Pharmaceutical Co., Ltd. |
Therapeutisches mittel für keratokonjunktive erkrankungen
|
WO2005042712A2
(en)
*
|
2003-10-28 |
2005-05-12 |
Reddy Us Therapeutics, Inc. |
Heterocyclic compounds and methods of making and using thereof
|
WO2005039571A1
(ja)
*
|
2003-10-29 |
2005-05-06 |
Santen Pharmaceutical Co., Ltd. |
角結膜障害治療剤
|
JP2005162735A
(ja)
*
|
2003-10-29 |
2005-06-23 |
Santen Pharmaceut Co Ltd |
角結膜障害治療剤
|
ATE498404T1
(de)
|
2003-12-09 |
2011-03-15 |
Novo Nordisk As |
Regulierung der nahrungspräferenz mit glp-1- agonisten
|
DK1723128T3
(da)
|
2004-01-06 |
2013-02-18 |
Novo Nordisk As |
Heteroarylurinstoffer og deres anvendelse som glucokinaseaktivatorer
|
US7470706B2
(en)
|
2004-01-31 |
2008-12-30 |
Sanofi-Aventis Deutschland Gmbh |
Cycloalkyl-substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments
|
US7498341B2
(en)
|
2004-01-31 |
2009-03-03 |
Sanofi Aventis Deutschland Gmbh |
Heterocyclically substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments
|
US7402674B2
(en)
|
2004-01-31 |
2008-07-22 |
Sanofi-Aventis Deutschland Gmbh, |
7-Phenylamino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments
|
DE102004005172A1
(de)
|
2004-02-02 |
2005-08-18 |
Aventis Pharma Deutschland Gmbh |
Indazolderivate als Inhibitoren der Hormon Sensitiven Lipase
|
EP1586573B1
(de)
|
2004-04-01 |
2007-02-07 |
Sanofi-Aventis Deutschland GmbH |
Oxadiazolone, Verfahren zu ihrer Herstellung sowie ihre Verwendung als Pharmazeutika
|
EP1758856A2
(de)
|
2004-05-04 |
2007-03-07 |
Novo Nordisk A/S |
Indolderivate zur behandlung von obesitas
|
DK1761540T3
(en)
|
2004-05-13 |
2016-11-21 |
Icos Corp |
Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase DELTA
|
EP1604988A1
(de)
|
2004-05-18 |
2005-12-14 |
Sanofi-Aventis Deutschland GmbH |
Pyridazinonderivate, Methoden, um selbige herzustellen, und ihre Verwendung als Pharmazeutika
|
US8410047B2
(en)
|
2004-06-11 |
2013-04-02 |
Novo Nordisk A/S |
Counteracting drug-induced obesity using GLP-1 agonists
|
EP1841749A1
(de)
|
2004-09-02 |
2007-10-10 |
Metabasis Therapeutics, Inc. |
Thiazol- und thiadiazolderivate als inhibitoren von tyrosinphosphatasen
|
US8263551B2
(en)
|
2004-11-22 |
2012-09-11 |
Novo Nordisk A/S |
Soluble, stable insulin-containing formulations with a protamine salt
|
JP2008521864A
(ja)
|
2004-12-03 |
2008-06-26 |
トランステック・ファーマ、インコーポレイテッド |
ヘテロ芳香族グルコキナーゼ活性化剤
|
DE102005026762A1
(de)
|
2005-06-09 |
2006-12-21 |
Sanofi-Aventis Deutschland Gmbh |
Azolopyridin-2-on-derivate als Inhibitoren von Lipasen und Phospholipasen
|
CN103110635A
(zh)
|
2005-07-04 |
2013-05-22 |
海波因特制药有限责任公司 |
组胺h3受体拮抗剂
|
CA2615938C
(en)
|
2005-07-14 |
2014-04-29 |
Novo-Nordisk A/S |
Urea glucokinase activators
|
WO2007015805A1
(en)
|
2005-07-20 |
2007-02-08 |
Eli Lilly And Company |
1-amino linked compounds
|
EP1931337B1
(de)
|
2005-09-29 |
2013-10-23 |
Sanofi |
Phenyl- und pyridinyl-1,2,4-oxadiazolon-derivate, verfahren zu ihrer herstellung und ihre verwendung als pharmazeutika
|
JP5198280B2
(ja)
|
2005-11-17 |
2013-05-15 |
イーライ リリー アンド カンパニー |
グルカゴン受容体アンタゴニスト、並びにその調製及び治療への使用
|
PL2383271T3
(pl)
|
2006-03-13 |
2013-12-31 |
Kyorin Seiyaku Kk |
Aminochinolony jako inhibitory GSK-3
|
JP2009531376A
(ja)
|
2006-03-28 |
2009-09-03 |
ハイ ポイント ファーマシューティカルズ,リミティド ライアビリティ カンパニー |
ヒスタミンh3受容体活性を有するベンゾチアゾール
|
TW200815377A
(en)
*
|
2006-04-24 |
2008-04-01 |
Astellas Pharma Inc |
Oxadiazolidinedione compound
|
NZ571972A
(en)
|
2006-05-29 |
2011-09-30 |
High Point Pharmaceuticals Llc |
3- (1, 3-benz0di0x0l-5-yl) -6- (4-cyclopropylpiperazin-1-yl) -pyridazine, its salts and solvates and its use as histamine h3 receptor antagonist
|
DE102006028862A1
(de)
|
2006-06-23 |
2007-12-27 |
Merck Patent Gmbh |
3-Amino-imidazo[1,2-a]pyridinderivate
|
RU2009108280A
(ru)
|
2006-08-08 |
2010-09-20 |
Санофи-Авентис (Fr) |
Ариламиноарилалкилзамещенные имидазолидин-2,4-дионы, способы их получения, содержащие эти соединения лекарственные средства и их применение
|
ES2377322T3
(es)
|
2006-11-15 |
2012-03-26 |
High Point Pharmaceuticals, Llc |
Nuevas 2-(2-hidroxifenil)benzotiadiazinas útiles para el tratamiento de la obesidad y la diabetes
|
US7915299B2
(en)
|
2006-11-15 |
2011-03-29 |
High Point Pharmaceuticals, Llc |
2-(2-hydroxyphenyl)benzimidazoles useful for treating obesity and diabetes
|
EP2099777B1
(de)
|
2007-01-11 |
2015-08-12 |
Novo Nordisk A/S |
Harnstoff-glucokinase-aktivatoren
|
DE102007002260A1
(de)
|
2007-01-16 |
2008-07-31 |
Sanofi-Aventis |
Verwendung von substituierten Pyranonsäurederivaten zur Herstellung von Medikamenten zur Behandlung des Metabolischen Syndroms
|
DE102007005045B4
(de)
|
2007-01-26 |
2008-12-18 |
Sanofi-Aventis |
Phenothiazin Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
|
DE102007008420A1
(de)
|
2007-02-21 |
2008-08-28 |
Merck Patent Gmbh |
Benzimidazolderivate
|
WO2008124072A1
(en)
*
|
2007-04-05 |
2008-10-16 |
The Board Of Regents Of The University Of Texas System |
Palmerolides: methods of preparation and derivatives thereof
|
US20080319221A1
(en)
|
2007-06-22 |
2008-12-25 |
Bernd Junker |
Esters of Pentahydroxyhexylcarbamoyl Alkanoic Acids
|
EP2025674A1
(de)
|
2007-08-15 |
2009-02-18 |
sanofi-aventis |
Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
|
AU2008299903B2
(en)
|
2007-09-11 |
2013-08-29 |
Kyorin Pharmaceutical Co., Ltd |
Cyanoaminoquinolones and tetrazoloaminoquinolones as GSK-3 inhibitors
|
CN101855229A
(zh)
|
2007-09-12 |
2010-10-06 |
埃迪威克斯生物科学公司 |
作为gsk-3抑制剂的螺环状氨基喹诺酮
|
DE102007048716A1
(de)
|
2007-10-11 |
2009-04-23 |
Merck Patent Gmbh |
Imidazo[1,2-a]pyrimidinderivate
|
TW200932219A
(en)
|
2007-10-24 |
2009-08-01 |
Astellas Pharma Inc |
Oxadiazolidinedione compound
|
DE102007054497B3
(de)
|
2007-11-13 |
2009-07-23 |
Sanofi-Aventis Deutschland Gmbh |
Neue kristalline Diphenylazetidinonhydrate und Verfahren zu deren Herstellung
|
DE102008017590A1
(de)
|
2008-04-07 |
2009-10-08 |
Merck Patent Gmbh |
Glucopyranosidderivate
|
CN101555214B
(zh)
|
2008-04-08 |
2012-07-11 |
北京嘉事联博医药科技有限公司 |
苯基环丁基酰胺衍生物及其光学异构体、制备方法和用途
|
WO2010003624A2
(en)
|
2008-07-09 |
2010-01-14 |
Sanofi-Aventis |
Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
|
US9492449B2
(en)
|
2008-11-13 |
2016-11-15 |
Gilead Calistoga Llc |
Therapies for hematologic malignancies
|
PT2355828T
(pt)
|
2008-11-13 |
2018-07-02 |
Gilead Calistoga Llc |
Terapias para malignidades hematológicas
|
KR20110088575A
(ko)
|
2008-11-21 |
2011-08-03 |
하이 포인트 파마슈티칼스, 엘엘씨 |
아다만틸 벤즈아미드 화합물
|
WO2010068601A1
(en)
|
2008-12-08 |
2010-06-17 |
Sanofi-Aventis |
A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
|
BRPI1008974A2
(pt)
|
2009-03-11 |
2017-06-06 |
Kyorin Seiyaku Kk |
composto, composição farmacêutica, e, método para tratar, prevenir ou melhorar uma doença mediada com gsk-3
|
BRPI1012333A2
(pt)
|
2009-03-24 |
2016-03-29 |
Gilead Calistoga Llc |
atropisômeros de derivados de 2-purinil-3-tolil-quinazolinonas e métodos de uso
|
ES2548253T3
(es)
|
2009-04-20 |
2015-10-15 |
Gilead Calistoga Llc |
Métodos para el tratamiento de tumores sólidos
|
WO2011011550A1
(en)
|
2009-07-21 |
2011-01-27 |
Calistoga Pharmaceuticals Inc. |
Treatment of liver disorders with pi3k inhibitors
|
WO2011023754A1
(en)
|
2009-08-26 |
2011-03-03 |
Sanofi-Aventis |
Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
|
AU2010302642A1
(en)
|
2009-10-02 |
2012-04-26 |
Sanofi |
Use of compounds with SGLT-1/SGLT-2 inhibitor activity for producing medicaments for treatment of bone diseases
|
WO2011104378A1
(en)
|
2010-02-26 |
2011-09-01 |
Novo Nordisk A/S |
Peptides for treatment of obesity
|
BR112012021231A2
(pt)
|
2010-02-26 |
2015-09-08 |
Basf Plant Science Co Gmbh |
método para acentuar o rendimento em plantas, planta, construto, uso de um construto, método para a produção de uma planta transgênica, partes coletáveis de uma planta, produtos derivados de uma planta, uso de um ácido nucleíco e método para a produção de um produto
|
WO2011107494A1
(de)
|
2010-03-03 |
2011-09-09 |
Sanofi |
Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
|
RU2559320C2
(ru)
|
2010-03-26 |
2015-08-10 |
Ново Нордиск А/С |
Новые аналоги глюкагона
|
DE102010015123A1
(de)
|
2010-04-16 |
2011-10-20 |
Sanofi-Aventis Deutschland Gmbh |
Benzylamidische Diphenylazetidinone, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
|
EP2582709B1
(de)
|
2010-06-18 |
2018-01-24 |
Sanofi |
Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
|
US8530413B2
(en)
|
2010-06-21 |
2013-09-10 |
Sanofi |
Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
|
TW201215387A
(en)
|
2010-07-05 |
2012-04-16 |
Sanofi Aventis |
Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
|
TW201215388A
(en)
|
2010-07-05 |
2012-04-16 |
Sanofi Sa |
(2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
|
TW201221505A
(en)
|
2010-07-05 |
2012-06-01 |
Sanofi Sa |
Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
|
EP2438930A1
(de)
|
2010-09-17 |
2012-04-11 |
Sanofi-Aventis Deutschland GmbH |
Prodrug mit einem exendinbindenden Konjugat
|
EP2670368A4
(de)
|
2011-02-03 |
2015-04-15 |
Pharmedica Ltd |
Neue im mund zersetzbare filme zur insulinverabreichung zwecks behandlung von diabetes
|
WO2012120054A1
(de)
|
2011-03-08 |
2012-09-13 |
Sanofi |
Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
|
EP2683701B1
(de)
|
2011-03-08 |
2014-12-24 |
Sanofi |
Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
|
US8895547B2
(en)
|
2011-03-08 |
2014-11-25 |
Sanofi |
Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
|
US8871758B2
(en)
|
2011-03-08 |
2014-10-28 |
Sanofi |
Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
|
EP2683699B1
(de)
|
2011-03-08 |
2015-06-24 |
Sanofi |
Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
|
US8901114B2
(en)
|
2011-03-08 |
2014-12-02 |
Sanofi |
Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
|
WO2012120051A1
(de)
|
2011-03-08 |
2012-09-13 |
Sanofi |
Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
|
EP2683704B1
(de)
|
2011-03-08 |
2014-12-17 |
Sanofi |
Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
|
EP2683702B1
(de)
|
2011-03-08 |
2014-12-24 |
Sanofi |
Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
|
CA2830974A1
(en)
|
2011-03-28 |
2012-10-04 |
Jesper F. Lau |
Novel glucagon analogues
|
EP2567959B1
(de)
|
2011-09-12 |
2014-04-16 |
Sanofi |
6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridin-4-carbonsäureamid-derivate als kinaseinhibitoren
|
WO2013037390A1
(en)
|
2011-09-12 |
2013-03-21 |
Sanofi |
6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
|
KR20140070612A
(ko)
|
2011-09-23 |
2014-06-10 |
노보 노르디스크 에이/에스 |
신규 글루카곤 유사체
|
WO2013045413A1
(en)
|
2011-09-27 |
2013-04-04 |
Sanofi |
6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
|
UA108713C2
(xx)
|
2011-11-11 |
2015-05-25 |
|
2-тіопіримідинони
|
KR20140133590A
(ko)
|
2012-03-05 |
2014-11-19 |
길리아드 칼리스토가 엘엘씨 |
(s)-2-(1-(9h-퓨린-6-일아미노)프로필)-5-플루오로-3-페닐퀴나졸린-4(3h)-온의 다형체 형태
|
EP2911655A1
(de)
|
2012-10-24 |
2015-09-02 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Tpl2-kinasehemmer zur vorbeugung oder behandlung von diabetes und zur förderung des überlebens von betazellen
|
WO2014170496A1
(en)
|
2013-04-18 |
2014-10-23 |
Novo Nordisk A/S |
Stable, protracted glp-1/glucagon receptor co-agonists for medical use
|
AU2014364414A1
(en)
|
2013-12-20 |
2016-06-30 |
Gilead Calistoga Llc |
Polymorphic forms of a hydrochloride salt of (S) -2-(1-(9H-purin-6-ylamino) propyl) -5-fluoro-3-phenylquinazolin-4 (3H) -one
|
NZ736970A
(en)
|
2013-12-20 |
2018-11-30 |
Gilead Calistoga Llc |
Process methods for phosphatidylinositol 3-kinase inhibitors
|
US10570184B2
(en)
|
2014-06-04 |
2020-02-25 |
Novo Nordisk A/S |
GLP-1/glucagon receptor co-agonists for medical use
|
CN106459005A
(zh)
|
2014-06-13 |
2017-02-22 |
吉利德科学公司 |
磷脂酰肌醇3‑激酶抑制剂
|
ES2805743T3
(es)
|
2015-03-24 |
2021-02-15 |
Inst Nat Sante Rech Med |
Método y composición farmacéutica para uso en el tratamiento de la diabetes
|
MX2017014128A
(es)
|
2015-05-05 |
2018-03-15 |
Pfizer |
2-tiopirimidinonas.
|
MA49883A
(fr)
|
2017-03-15 |
2021-04-21 |
Novo Nordisk As |
Composés bicycliques aptes à se lier au récepteur de mélanocortine 4
|
US20210221867A1
(en)
|
2018-05-15 |
2021-07-22 |
Novo Nordisk A/S |
Compounds Capable of Binding to Melanocortin 4 Receptor
|
WO2020053414A1
(en)
|
2018-09-14 |
2020-03-19 |
Novo Nordisk A/S |
Bicyclic compounds capable of acting as melanocortin 4 receptor agonists
|
CN110128309A
(zh)
*
|
2019-06-13 |
2019-08-16 |
郑州大学 |
一种新型的2-巯基异丁酸制备方法
|